Vertex 809-011b

A Phase 3, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Purpose: A study with Combination Therapy Ivacaftor and Lumacaftor in Children 6-11 for Cystic Fibrosis homozygote genotype DeltaF508. 


Sponsor: Vertex Pharmaceuticals


Principal Investigator: Cori Daines, MD


Contact Information:

Osmara Y. Molina de Rodriguez, MS

Cell: (520) 891-6767 or Office: (520) 626-3910

Study Status: